Journal articles: 'Drug Delivery engineering'

1

Costa, Pedro F. "Bone Tissue Engineering Drug Delivery." Current Molecular Biology Reports 1, no. 2 (April 11, 2015): 87–93. http://dx.doi.org/10.1007/s40610-015-0016-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yang, Xiaosong, Shizhu Chen, Xiao Liu, Miao Yu, and Xiaoguang Liu. "Drug Delivery Based on Nanotechnology for Target Bone Disease." Current Drug Delivery 16, no. 9 (December 4, 2019): 782–92. http://dx.doi.org/10.2174/1567201816666190917123948.

Full text

Abstract:

Bone diseases are a serious problem in modern human life. With the coming acceleration of global population ageing, this problem will become more and more serious. Due to the specific physiological characteristics and local microenvironment of bone tissue, it is difficult to deliver drugs to the lesion site. Therefore, the traditional orthopedic medicine scheme has the disadvantages of high drug frequency, large dose and relatively strong side effects. How to target deliver drugs to the bone tissue or even target cells is the focus of the development of new drugs. Nano drug delivery system with a targeting group can realize precise delivery of orthopedic drugs and effectively reduce the systemic toxicity. In addition, the application of bone tissue engineering scaffolds and biomedical materials to realize in situ drug delivery also are research hotspot. In this article, we briefly review the application of nanotechnology in targeted therapies for bone diseases.

APA, Harvard, Vancouver, ISO, and other styles

3

Liang, Yujie, Li Duan, Jianping Lu, and Jiang Xia. "Engineering exosomes for targeted drug delivery." Theranostics 11, no. 7 (2021): 3183–95. http://dx.doi.org/10.7150/thno.52570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sarker, Dipak. "Engineering of Nanoemulsions for Drug Delivery." Current Drug Delivery 2, no. 4 (October 1, 2005): 297–310. http://dx.doi.org/10.2174/156720105774370267.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Liang, Yujie, Li Duan, Jianping Lu, and Jiang Xia. "Engineering exosomes for targeted drug delivery." Theranostics 11, no. 7 (2021): 3183–95. http://dx.doi.org/10.7150/thno.52570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tiwari, Ashutosh. "Drug Delivery & Tissue Engineering Conference." Advanced Materials Letters 8, no. 9 (September 1, 2017): 883. http://dx.doi.org/10.5185/amlett.2017/9001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hu, Quanyin, Hunter N. Bomba, and Zhen Gu. "Engineering platelet-mimicking drug delivery vehicles." Frontiers of Chemical Science and Engineering 11, no. 4 (February 15, 2017): 624–32. http://dx.doi.org/10.1007/s11705-017-1614-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ladewig, Katharina. "Drug delivery in soft tissue engineering." Expert Opinion on Drug Delivery 8, no. 9 (June 16, 2011): 1175–88. http://dx.doi.org/10.1517/17425247.2011.588698.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Raemdonck, Koen, Joseph Demeester, and Stefaan De Smedt. "Advanced nanogel engineering for drug delivery." Soft Matter 5, no. 4 (2009): 707–15. http://dx.doi.org/10.1039/b811923f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hacisalihzade, S. S. "Control engineering and therapeutic drug delivery." IEEE Control Systems Magazine 9, no. 4 (June 1989): 44–45. http://dx.doi.org/10.1109/37.24840.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Biondi, Marco, Francesca Ungaro, Fabiana Quaglia, and Paolo Antonio Netti. "Controlled drug delivery in tissue engineering." Advanced Drug Delivery Reviews 60, no. 2 (January 2008): 229–42. http://dx.doi.org/10.1016/j.addr.2007.08.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Chow, Albert H. L., Henry H. Y. Tong, Pratibhash Chattopadhyay, and Boris Y. Shekunov. "Particle Engineering for Pulmonary Drug Delivery." Pharmaceutical Research 24, no. 3 (January 24, 2007): 411–37. http://dx.doi.org/10.1007/s11095-006-9174-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

chilukala, Swathi. "Gastro retentive Drug Delivery of Cyclobenzaprine Hydrochloride." Gastroenterology Pancreatology and Hepatobilary Disorders 2, no. 1 (December 5, 2018): 01–03. http://dx.doi.org/10.31579/2641-5194/006.

Full text

Abstract:

Drugs that are easily absorbed from the GI tract and have a short half-life are eliminated quickly from the blood circulation, require frequent dosing. To avoid this problem, the oral controlled release formulations are being developed. Gastro-retentive dosage forms have the potential from use as controlled release systems. The purpose of this research is to develop the gastro retentive drug delivery system of centrally acting alpha adrenergic agonist cyclobenzaprine Hydrochloride (cyclobenzaprine HCl). It is well absorbed from the upper part of the GIT, due to short gastric residence time the bioavailability is low and hence it is need to develop a dosage form that releases the drug in stomach using gastro retentive system. Different formulations of cyclobenzaprine HCl gastro-retentive floating tablets were prepared by wet granulation method using various concentrations of HPMC K4M / HPMC K100M and combination of Psyllium husk and HPMC K100M as matrix forming agent. Sodium bicarbonate and citric acid were used as a gas generating agent that helps in maintaining the buoyancy. The prepared cyclobenzaprine HCl gastro-retentive floating granules were subjected to pre-compression properties to comply with pharmacopoeial limits and the prepared gastro-retentive floating tablets were characterized for weight variation, hardness, thickness and friability drug content, swelling studies. The floating lag time of all formulation is good and the Total floating time of all the formulations was >12 hours. The tablets were evaluated for in vitro release characteristics for 12hrs in 0.1N HCl at 37 oC and from this in vitro release studies the formulations F-5, F-9 and F-15 exhibited good controlled release profile of about 96.0%, 94.5% and 95.0% when compared with other formulations while floating on the dissolution medium.

APA, Harvard, Vancouver, ISO, and other styles

14

Baker, Dale. "Drug delivery." Annals of Biomedical Engineering 25, no. 1 (January 1997): S—3. http://dx.doi.org/10.1007/bf02647344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

HENRY, CELIA M. "DRUG DELIVERY." Chemical & Engineering News 80, no. 34 (August 26, 2002): 39–47. http://dx.doi.org/10.1021/cen-v080n034.p039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Webster, Andrew A. "New Publication: Drug Delivery: Engineering Principles for Drug Therapy." Journal of Pharmacy Technology 17, no. 6 (November 2001): 304. http://dx.doi.org/10.1177/875512250101700619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Kim, Yu Jeong. "Ophthalmic Drug Delivery System Using Contact Lens." Annals of Optometry and Contact Lens 22, no. 2 (June 25, 2023): 48–51. http://dx.doi.org/10.52725/aocl.2023.22.2.48.

Full text

Abstract:

Most of the ophthalmic drug delivery methods for treating ocular diseases are eye drops. However, topical eye drop instillation has limitations in that the bioavailability is low, side effects may occur due to systemic absorption, and patient compliance is low. Various delivery methods have been attempted to effectively deliver ophthalmic drugs, and among them, a drug delivery system using a contact lens will be reviewed.

APA, Harvard, Vancouver, ISO, and other styles

18

Salmoria, G. V., F. E. Vieira, G. B. Ghizoni, I. M. Gindri, and L. A. Kanis. "Additive Manufacturing of PE/Fluorouracil Waffles for Implantable Drug Delivery in Bone Cancer Treatment." International Journal of Engineering Research & Science 3, no. 6 (June 30, 2017): 62–70. http://dx.doi.org/10.25125/engineering-journal-ijoer-jun-2017-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Illum, Lisbeth, and Stanley S. Davis. "Drug delivery." Current Opinion in Biotechnology 2, no. 2 (April 1991): 254–59. http://dx.doi.org/10.1016/0958-1669(91)90018-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Kakran, Mitali, and Lin Li. "Carbon Nanomaterials for Drug Delivery." Key Engineering Materials 508 (March 2012): 76–80. http://dx.doi.org/10.4028/www.scientific.net/kem.508.76.

Full text

Abstract:

Carbon Nanotubes (CNTs) and Graphene Have Attracted Tremendous Attention as the Most Promising Carbon Nanomaterials in the 21st Century for a Variety of Applications such as Electronics, Biomedical Engineering, Tissue Engineering, Neuroengineering, Gene Therapy and Biosensor Technology. For the Biomedical Applications, Cnts Have Been Utilized over Existing Drug Delivery Vectors due to their Ability to Cross Cell Membranes Easily and their High Aspect Ratio as Well as High Surface Area, which Provides Multiple Attachment Sites for Drug Targeting. Besides, it Has Also Been Proved that the Functionalization of CNTs May Remarkably Reduce their Cytotoxic Effects and at the Same Time Increase their Biocompatibility. So, the Functionalized CNTs Are Safer than Pristine or Purified CNTs, Thus Offering the Potential Exploitation of Nanotubes for Drug Administration. On the other Hand, More Recently Graphene and its Derivatives Have Been Enormously Investigated in the Biological Applications because of their Biocompatibility, Unique Conjugated Structure, Relatively Low Cost and Availability on both Sides of a Single Sheet for Drug Binding. In Our Study, we Have Covalently Functionalized Multiwalled Carbon Nanotubes (MWCNTs) and Graphene Oxide (GO) with Highly Hydrophilic and Biocompatible Excipients in Order to Increase their Aqueous Solubility and Biocompatibility. Various Excipients Used Were Polyvinyl Alcohol, Pluronic F38, Tween 80 and Maltodextrin. The Poorly Water-Soluble Anticancer Drugs such as, Camptothecin and Ellagic Acid, Were Loaded onto the Functionalized MWCNTs and GO via Non-Covalent Interactions. Furthermore, Drug Loading and Cytotoxic Activity of Drugs Incorporated with the Functionalized MWCNTs and GO as Nanocarriers Were Also Investigated. Drugs Loaded on both Carbon Nanocarriers Exhibited a Higher Cytotoxic Activity than Free Drug. On the other Hand, No Significant Toxicity Was Found even at Higher Concentrations when the Cells Were Incubated with the Functionalized Mwcnts and GO. Therefore, both these Functionalized Carbon Nanomaterials Are Ideal Carriers for Drug Delivery.

APA, Harvard, Vancouver, ISO, and other styles

21

D. Gidde, Nikita, Komal A. Karande, Snehal S. Jadhav, Ruksar S. Mistry, Pratiksha A. Mhetre, and Sourabh D. Joshi. "Microsponge : An Overview." Journal of University of Shanghai for Science and Technology 23, no. 11 (November 25, 2021): 671–82. http://dx.doi.org/10.51201/jusst/21/11949.

Full text

Abstract:

Microsponges are a revolutionary way of medication administration that has a number of advantages. The Microsponges drug delivery system is used to increase the performance of medications that are delivered orally, parenterally, or topically in a variety of conditions. Microsponge is a new technology for controlling medication release and delivering drugs to precise targets. Microsponge technology has been used in topical medicinal solutions to allow for regulated active drug release into the skin, lowering systemic exposure and reducing local cutaneous reactions to active pharmaceuticals. This review discusses the preparation procedures, evaluation methodologies, drug release mechanism, and physical characterization of Microsponges in relation to a Microsponges delivery system. Microsponges are used to deliver a pharmaceutical active component at a low dose while simultaneously improving stability, reducing adverse effects, and modifying drug release.

APA, Harvard, Vancouver, ISO, and other styles

22

Municoy, Sofia, María I. Álvarez Echazú, Pablo E. Antezana, Juan M. Galdopórpora, Christian Olivetti, Andrea M. Mebert, María L. Foglia, et al. "Stimuli-Responsive Materials for Tissue Engineering and Drug Delivery." International Journal of Molecular Sciences 21, no. 13 (July 2, 2020): 4724. http://dx.doi.org/10.3390/ijms21134724.

Full text

Abstract:

Smart or stimuli-responsive materials are an emerging class of materials used for tissue engineering and drug delivery. A variety of stimuli (including temperature, pH, redox-state, light, and magnet fields) are being investigated for their potential to change a material’s properties, interactions, structure, and/or dimensions. The specificity of stimuli response, and ability to respond to endogenous cues inherently present in living systems provide possibilities to develop novel tissue engineering and drug delivery strategies (for example materials composed of stimuli responsive polymers that self-assemble or undergo phase transitions or morphology transformations). Herein, smart materials as controlled drug release vehicles for tissue engineering are described, highlighting their potential for the delivery of precise quantities of drugs at specific locations and times promoting the controlled repair or remodeling of tissues.

APA, Harvard, Vancouver, ISO, and other styles

23

Bernhard, Stéphane, and Mark W. Tibbitt. "Supramolecular engineering of hydrogels for drug delivery." Advanced Drug Delivery Reviews 171 (April 2021): 240–56. http://dx.doi.org/10.1016/j.addr.2021.02.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

V. Gaikwad, Vikas, Abasaheb B. Patil, and Madhuri V. Gaikwad. "Scaffolds for Drug Delivery in Tissue Engineering." International Journal of Pharmaceutical Sciences and Nanotechnology 1, no. 2 (August 31, 2008): 113–23. http://dx.doi.org/10.37285/ijpsn.2008.1.2.1.

Full text

Abstract:

Scaffolds are used for drug delivery in tissue engineering as this system is a highly porous structure to allow tissue growth. Although several tissues in the body can regenerate, other tissue such as heart muscles and nerves lack regeneration in adults. However, these can be regenerated by supplying the cells generated using tissue engineering from outside. For instance, in many heart diseases, there is need for heart valve transplantation and unfortunately, within 10 years of initial valve replacement, 50–60% of patients will experience prosthesis associated problems requiring reoperation. This could be avoided by transplantation of heart muscle cells that can regenerate. Delivery of these cells to the respective tissues is not an easy task and this could be done with the help of scaffolds. In situ gel forming scaffolds can also be used for the bone and cartilage regeneration. They can be injected anywhere and can take the shape of a tissue defect, avoiding the need for patient specific scaffold prefabrication and they also have other advantages. Scaffolds are prepared by biodegradable material that result in minimal immune and inflammatory response. Some of the very important issues regarding scaffolds as drug delivery systems is reviewed in this article.

APA, Harvard, Vancouver, ISO, and other styles

25

Langer, Robert. "Biomaterials for Drug Delivery and Tissue Engineering." MRS Bulletin 31, no. 6 (June 2006): 477–85. http://dx.doi.org/10.1557/mrs2006.122.

Full text

Abstract:

AbstractThe following article is an edited transcript based on the Von Hippel Award presentation by Robert Langer of the Massachusetts Institute of Technology on November 30, 2005, at the Materials Research Society Fall Meeting in Boston. Langer was honored with MRS's highest award for his “pioneering accomplishments in the science and application of biomaterials in drug delivery and tissue engineering, particularly in inventing the use of materials for protein and DNA delivery, and for his achievements in interdisciplinary research which have generated new medical products, created new fields of biomaterials science, and inspired research programs throughout the world.”

APA, Harvard, Vancouver, ISO, and other styles

26

Saltzman, W. Mark, and William L. Olbricht. "Building drug delivery into tissue engineering design." Nature Reviews Drug Discovery 1, no. 3 (March 2002): 177–86. http://dx.doi.org/10.1038/nrd744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Seachrist, L. "Researchers Engineering New Cancer Drug Delivery Systems." JNCI Journal of the National Cancer Institute 85, no. 22 (November 17, 1993): 1797–98. http://dx.doi.org/10.1093/jnci/85.22.1797.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Murphy, J. "Protein engineering and design for drug delivery." Current Opinion in Structural Biology 6, no. 4 (August 1996): 541–45. http://dx.doi.org/10.1016/s0959-440x(96)80121-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Chen, Zhaowei, Quanyin Hu, and Zhen Gu. "Leveraging Engineering of Cells for Drug Delivery." Accounts of Chemical Research 51, no. 3 (February 15, 2018): 668–77. http://dx.doi.org/10.1021/acs.accounts.7b00526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Jana, Soumen, Robert D. Simari, Daniel B. Spoon, and Amir Lerman. "Drug delivery in aortic valve tissue engineering." Journal of Controlled Release 196 (December 2014): 307–23. http://dx.doi.org/10.1016/j.jconrel.2014.10.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Correa, Santiago, Erik C. Dreaden, Li Gu, and Paula T. Hammond. "Engineering nanolayered particles for modular drug delivery." Journal of Controlled Release 240 (October 2016): 364–86. http://dx.doi.org/10.1016/j.jconrel.2016.01.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Boccaccini, Aldo R. "Bioceramics for tissue engineering and drug delivery." Advances in Applied Ceramics 107, no. 5 (October 2008): 233. http://dx.doi.org/10.1179/174367608x363493.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Friess, W. "Collagen in drug delivery and tissue engineering." Advanced Drug Delivery Reviews 55, no. 12 (November 28, 2003): 1529–30. http://dx.doi.org/10.1016/j.addr.2003.08.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Murakami, Tatsuya. "Phospholipid nanodisc engineering for drug delivery systems." Biotechnology Journal 7, no. 6 (May 14, 2012): 762–67. http://dx.doi.org/10.1002/biot.201100508.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Zarenezhad, Elham, Mahrokh Marzi, Hussein T. Abdulabbas, Saade Abdalkareem Jasim, Seyed Amin Kouhpayeh, Silvia Barbaresi, Shiva Ahmadi, and Abdolmajid Ghasemian. "Bilosomes as Nanocarriers for the Drug and Vaccine Delivery against Gastrointestinal Infections: Opportunities and Challenges." Journal of Functional Biomaterials 14, no. 9 (September 1, 2023): 453. http://dx.doi.org/10.3390/jfb14090453.

Full text

Abstract:

The gastrointestinal tract (GIT) environment has an intricate and complex nature, limiting drugs’ stability, oral bioavailability, and adsorption. Additionally, due to the drugs’ toxicity and side effects, renders are continuously seeking novel delivery systems. Lipid-based drug delivery vesicles have shown various loading capacities and high stability levels within the GIT. Indeed, most vesicular platforms fail to efficiently deliver drugs toward this route. Notably, the stability of vesicular constructs is different based on the different ingredients added. A low GIT stability of liposomes and niosomes and a low loading capacity of exosomes in drug delivery have been described in the literature. Bilosomes are nonionic, amphiphilic, flexible surfactant vehicles that contain bile salts for the improvement of drug and vaccine delivery. The bilosomes’ stability and plasticity in the GIT facilitate the efficient carriage of drugs (such as antimicrobial, antiparasitic, and antifungal drugs), vaccines, and bioactive compounds to treat infectious agents. Considering the intricate and harsh nature of the GIT, bilosomal formulations of oral substances have a remarkably enhanced delivery efficiency, overcoming these conditions. This review aimed to evaluate the potential of bilosomes as drug delivery platforms for antimicrobial, antiviral, antifungal, and antiparasitic GIT-associated drugs and vaccines.

APA, Harvard, Vancouver, ISO, and other styles

36

Tian, Bo, Evan Bilsbury, Sean Doherty, Sean Teebagy, Emma Wood, Wenqi Su, Guangping Gao, and Haijiang Lin. "Ocular Drug Delivery: Advancements and Innovations." Pharmaceutics 14, no. 9 (September 13, 2022): 1931. http://dx.doi.org/10.3390/pharmaceutics14091931.

Full text

Abstract:

Ocular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of “drug delivery” for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.

APA, Harvard, Vancouver, ISO, and other styles

37

Desai, Preshita P., Sanyat S. Mapara, and Vandana B. Patravale. "Crystal Engineering: Upcoming Paradigm for Efficacious Pulmonary Drug Delivery." Current Pharmaceutical Design 24, no. 21 (October 15, 2018): 2438–55. http://dx.doi.org/10.2174/1381612824666180518080948.

Full text

Abstract:

Background and objective: Pulmonary drug delivery has transformed over a past few decades from being a platform for local pulmonary disease treatment to systemic drug delivery opportunities. In case of pulmonary delivery systems, particle properties are critical as they affect inhalation efficacy, pulmonary deposition, drug delivery and overall performance. With this in view, particle engineering has emerged as an advanced science that helps in designing of efficacious pulmonary delivery systems. Among various particle engineering branches, crystal engineering is being extensively explored as it provides an opportunity to optimize particles at morphological, physicochemical and molecular levels which are essential to understand the role of crystal engineering in pulmonary drug delivery. Methods: A thorough literature survey in the field of crystal engineering approaches explored for pulmonary drug delivery was conducted and the collected data was meticulously studied and summarized. Results: In the review, pulmonary system is discussed with respect to various sites for drug deposition in respiratory tract, mechanism of drug deposition and clearance. Further, critical crystal parameters are discussed in-depth and various crystal engineering methods are summarized with emphasis on their impact on pulmonary delivery. Also, inhalation devices are overviewed to understand their performance in relation to crystal based pulmonary formulations. Conclusion: The review enabled a detailed insight on crystal engineering approaches for design of pulmonary delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

38

Ng, Jaryl Chen Koon, Daniel Wee Yee Toong, Valerie Ow, Su Yin Chaw, Hanwei Toh, Philip En Hou Wong, Subbu Venkatraman, et al. "Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation." Nanomedicine 17, no. 5 (February 2022): 325–47. http://dx.doi.org/10.2217/nnm-2021-0288.

Full text

Abstract:

Drug-delivery systems in cardiovascular applications regularly include the use of drug-eluting stents and drug-coated balloons to ensure sufficient drug transfer and efficacy in the treatment of cardiovascular diseases. In addition to the delivery of antiproliferative drugs, the use of growth factors, genetic materials, hormones and signaling molecules has led to the development of different nanoencapsulation techniques for targeted drug delivery. The review will cover drug delivery and coating mechanisms in current drug-eluting stents and drug-coated balloons, novel innovations in drug-eluting stent technologies and drug encapsulation in nanocarriers for delivery in vascular diseases. Newer technologies and advances in nanoencapsulation techniques, such as the use of liposomes, nanogels and layer-by-layer coating to deliver therapeutics in the cardiovascular space, will be highlighted.

APA, Harvard, Vancouver, ISO, and other styles

39

Nagarajan, Sakthivel, Céline Pochat-Bohatier, Sébastien Balme, Philippe Miele, S. Narayana Kalkura, and Mikhael Bechelany. "Electrospun fibers in regenerative tissue engineering and drug delivery." Pure and Applied Chemistry 89, no. 12 (November 27, 2017): 1799–808. http://dx.doi.org/10.1515/pac-2017-0511.

Full text

Abstract:

AbstractElectrospinning is a versatile technique to produce micron or nano sized fibers using synthetic or bio polymers. The unique structural characteristic of the electrospun mats (ESM) which mimics extracellular matrix (ECM) found influential in regenerative tissue engineering application. ESM with different morphologies or ESM functionalizing with specific growth factors creates a favorable microenvironment for the stem cell attachment, proliferation and differentiation. Fiber size, alignment and mechanical properties affect also the cell adhesion and gene expression. Hence, the effect of ESM physical properties on stem cell differentiation for neural, bone, cartilage, ocular and heart tissue regeneration will be reviewed and summarized. Electrospun fibers having high surface area to volume ratio present several advantages for drug/biomolecule delivery. Indeed, controlling the release of drugs/biomolecules is essential for sustained delivery application. Various possibilities to control the release of hydrophilic or hydrophobic drug from the ESM and different electrospinning methods such as emulsion electrospinning and coaxial electrospinning for drug/biomolecule loading are summarized in this review.

APA, Harvard, Vancouver, ISO, and other styles

40

Guo, Mengqin, Tingting Peng, Chuanbin Wu, Xin Pan, and Zhengwei Huang. "Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis." Bioengineering 10, no. 6 (June 17, 2023): 727. http://dx.doi.org/10.3390/bioengineering10060727.

Full text

Abstract:

Idiopathic pulmonary fibrosis (IPF) refers to chronic progressive fibrotic interstitial pneumonia. It is called a “tumor-like disease” and cannot be cured using existing clinical drugs. Therefore, new treatment options are urgently needed. Studies have proven that ferroptosis is closely related to the development of IPF, and ferroptosis inhibitors can slow down the occurrence of IPF by chelating iron or reducing lipid peroxidation. For example, the ferroptosis inhibitor deferoxamine (DFO) was used to treat a mouse model of pulmonary fibrosis, and DFO successfully reversed the IPF phenotype and increased the survival rate of mice from 50% to 90%. Given this, we perceive that the treatment of IPF by delivering ferroptosis inhibitors is a promising option. However, the delivery of ferroptosis inhibitors faces two bottlenecks: low solubility and targeting. For one thing, we consider preparing ferroptosis inhibitors into nanomedicines to improve solubility. For another thing, we propose to deliver nanomedicines through pulmonary drug-delivery system (PDDS) to improve targeting. Compared with oral or injection administration, PDDS can achieve better delivery and accumulation in the lung, while reducing the systemic exposure of the drug, and is an efficient and safe drug-delivery method. In this paper, three possible nanomedicines for PDDS and the preparation methods thereof are proposed to deliver ferroptosis inhibitors for the treatment of IPF. Proper administration devices and challenges in future applications are also discussed. In general, this perspective proposes a promising strategy for the treatment of IPF based on inhalable nanomedicines carrying ferroptosis inhibitors, which can inspire new ideas in the field of drug development and therapy of IPF.

APA, Harvard, Vancouver, ISO, and other styles

41

Wei, Xinyue, Sihang Liu, Yifeng Cao, Zhen Wang, and Shengfu Chen. "Polymers in Engineering Extracellular Vesicle Mimetics: Current Status and Prospective." Pharmaceutics 15, no. 5 (May 14, 2023): 1496. http://dx.doi.org/10.3390/pharmaceutics15051496.

Full text

Abstract:

The maintenance of a high delivery efficiency by traditional nanomedicines during cancer treatment is a challenging task. As a natural mediator for short-distance intercellular communication, extracellular vesicles (EVs) have garnered significant attention owing to their low immunogenicity and high targeting ability. They can load a variety of major drugs, thus offering immense potential. In order to overcome the limitations of EVs and establish them as an ideal drug delivery system, polymer-engineered extracellular vesicle mimics (EVMs) have been developed and applied in cancer therapy. In this review, we discuss the current status of polymer-based extracellular vesicle mimics in drug delivery, and analyze their structural and functional properties based on the design of an ideal drug carrier. We anticipate that this review will facilitate a deeper understanding of the extracellular vesicular mimetic drug delivery system, and stimulate the progress and advancement of this field.

APA, Harvard, Vancouver, ISO, and other styles

42

Nitsch, Monica J., and Umesh V. Banakar. "Implantable Drug Delivery." Journal of Biomaterials Applications 8, no. 3 (January 1994): 247–84. http://dx.doi.org/10.1177/088532829400800305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

SANDERS, HOWARD J. "Improved Drug Delivery." Chemical & Engineering News 63, no. 13 (April 1985): 30–4048. http://dx.doi.org/10.1021/cen-v063n013.p030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Shaikh, Afroj A., Jaydeep B. Pawar, Sachin J. Anbhule, and Vaibhav V. Kakade. "Review on nanoparticles for topical drug delivery." International Journal of Pharmaceutical Chemistry and Analysis 10, no. 1 (April 15, 2023): 8–14. http://dx.doi.org/10.18231/j.ijpca.2023.003.

Full text

Abstract:

An overview of the use of nanoparticles for topical drug delivery will be given in this review paper. Several experiments have been conducted in the past 25 years to remove some of the obstacles to skin delivery. These investigations have led to a rather modest progress in technology. A more recent method involved increasing the medication's concentration in the carrier to increase drug flow into and through the skin. Hydrophobic and hydrophilic medications can be delivered using nanoparticles, which have the ability to release drugs under regulated conditions over an extended period of time. It also increases patient compliance. Liposomes and solid lipid nanoparticles have the potential to be useful as topical medication delivery methods.

APA, Harvard, Vancouver, ISO, and other styles

45

Wang, Tian-Zuo, Xin-Xin Liu, Si-Yu Wang, Yan Liu, Xin-Yang Pan, Jing-Jie Wang, and Kai-Hui Nan. "Engineering Advanced Drug Delivery Systems for Dry Eye: A Review." Bioengineering 10, no. 1 (December 31, 2022): 53. http://dx.doi.org/10.3390/bioengineering10010053.

Full text

Abstract:

Dry eye disease (DED) is a widespread and frequently reported multifactorial ocular disease that not only causes ocular discomfort but also damages the cornea and conjunctiva. At present, topical administration is the most common treatment modality for DED. Due to the existence of multiple biological barriers, instilled drugs generally exhibit short action times and poor penetration on the ocular surface. To resolve these issues, several advanced drug delivery systems have been proposed. This review discusses new dosage forms of drugs for the treatment of DED in terms of their characteristics and advantages. Innovative formulations that are currently available in the market and under clinical investigation are elaborated. Meanwhile, their deficiencies are discussed. It is envisioned that the flourishing of advanced drug delivery systems will lead to improved management of DED in the near future.

APA, Harvard, Vancouver, ISO, and other styles

46

Purohit, Arpana, Sameeksha Jain, Prakhar Nema, Harshna Vishwakarma, and Prateek Kumar Jain. "Intelligent or Smart Polymers: Advance in Novel Drug Delivery." Journal of Drug Delivery and Therapeutics 12, no. 5 (September 15, 2022): 208–16. http://dx.doi.org/10.22270/jddt.v12i5.5578.

Full text

Abstract:

Novel drug delivery system utilizing smart polymer to get significant and attracting changes in the targeting of drugs, increasing the bioavailability of drugs, enhancement patient compliance and gene therapy. The scientific community tries to mimic nature in the way that living organisms adopt their behavior as a function of environmental conditions to improve survival. In this sense, smart polymers offer materials that respond to numerous stimuli (temperature, pH, electric and magnetic fields, light intensity, biological molecules, etc.), and scientists must devise the best way to apply them in all research areas. Smart polymers are representing promising means for targeted drug delivery, enhanced drug delivery, gene therapy, actuator stimuli and protein folders. Smart polymers are very promising applicants in drug delivery, tissue engineering, cell culture, gene carriers, textile engineering, oil recovery, radioactive wastage and protein purification. The study is focused on the entire features of smart polymers and their most recent and relevant applications. Keywords: Smart polymer, Novel drug delivery system, Stimuli, Gene therapy

APA, Harvard, Vancouver, ISO, and other styles

47

P, Nagaraju, Krishnachaithanya K, Srinivas V.D.N, and Padma S.V.N. "Nanosuspensions: A Promising Drug Delivery Systems." International Journal of Pharmaceutical Sciences and Nanotechnology 2, no. 4 (February 28, 2010): 679–84. http://dx.doi.org/10.37285/ijpsn.2009.2.4.1.

Full text

Abstract:

One of the critical problems associated with poorly soluble drugs is low bioavailability and or erratic absorption. The problem is even more complex for drugs such as itraconazole and Carbamazepine (belonging to BCS CLASS II) as they are poorly soluble in both aqueous and organic media, and for those drugs having a log P value of 2. There are number of formulation approaches to resolve the problems of low solubility and low bioavailability. But all those have some limitations and hence have limited utility in solubility enhancement. Nanotechnology can be used to resolve these problems associated with conventional approaches. Nanotechnology is defined as the science and engineering carried out in the nanoscale that is 10-9 meters. Nanosuspensions consist of the pure poorly water-soluble drug without any matrix material suspended in dispersion. A nanosuspension not only solves the problems of poor solubility and bioavailability but also alters the pharmacokinetics of drug and thus improves drug safety and efficacy

APA, Harvard, Vancouver, ISO, and other styles

48

Han, Yohan, Timothy W. Jones, Saugata Dutta, Yin Zhu, Xiaoyun Wang, S. Priya Narayanan, Susan C. Fagan, and Duo Zhang. "Overview and Update on Methods for Cargo Loading into Extracellular Vesicles." Processes 9, no. 2 (February 15, 2021): 356. http://dx.doi.org/10.3390/pr9020356.

Full text

Abstract:

The enormous library of pharmaceutical compounds presents endless research avenues. However, several factors limit the therapeutic potential of these drugs, such as drug resistance, stability, off-target toxicity, and inadequate delivery to the site of action. Extracellular vesicles (EVs) are lipid bilayer-delimited particles and are naturally released from cells. Growing evidence shows that EVs have great potential to serve as effective drug carriers. Since EVs can not only transfer biological information, but also effectively deliver hydrophobic drugs into cells, the application of EVs as a novel drug delivery system has attracted considerable scientific interest. Recently, EVs loaded with siRNA, miRNA, mRNA, CRISPR/Cas9, proteins, or therapeutic drugs show improved delivery efficiency and drug effect. In this review, we summarize the methods used for the cargo loading into EVs, including siRNA, miRNA, mRNA, CRISPR/Cas9, proteins, and therapeutic drugs. Furthermore, we also include the recent advance in engineered EVs for drug delivery. Finally, both advantages and challenges of EVs as a new drug delivery system are discussed. Here, we encourage researchers to further develop convenient and reliable loading methods for the potential clinical applications of EVs as drug carriers in the future.

APA, Harvard, Vancouver, ISO, and other styles

49

Edelman, Blazer R., and Helen M. Nugent. "Local Drug Delivery and Tissue Engineering Regulate Vascular Injury." Current Pharmaceutical Design 3, no. 6 (December 1997): 529–44. http://dx.doi.org/10.2174/138161280306221010110930.

Full text

Abstract:

Abstract: It has become apparent that mechanical interventions designed to alleviate atherosclerotic vascular disease are beset by accelerated vascular diseases of their own. A multitude of agents have been directed against one or more of the cellular events thought to be involved in this process known as restenosis. Most of these agents suppress smooth muscle cell growth in tissue culture and in animal models, and yet no drug to date has shown any demonstrable benefit against human disease. This may be due to the suboptimal manner in which these drugs were administered. It has been demonstrated that far more beneficial effects are observed if one matches the delivery of a drug to the natural release of endogenous growth regulators. Controlled release of heparin from polymeric matrices inhibited smooth muscle cell proliferation following injury to vascular endothelium in a manner more efficient than in systemic administration. Moreover, the biologic control achieved by the endothelium is not due to one or several compounds, but rather to the concomitant presence and complimentary activity of all the cell-based products. Perivascular implantation of tissue engineered endothelial cell implants around injured arteries reduced intimal hyperplasia far better than isolated administration of heparin. Thus the coupling of polymer based drug delivery technology and tissue engineering with the science of molecular and cell biology provides a means to understanding the paradox of restenosis and even potential therapies.

APA, Harvard, Vancouver, ISO, and other styles

50

Uzunalli, Gozde, and Mustafa O. Guler. "Peptide gels for controlled release of proteins." Therapeutic Delivery 11, no. 3 (March 2020): 193–211. http://dx.doi.org/10.4155/tde-2020-0011.

Full text

Abstract:

Treatment strategies in clinics have been shifting from small molecules to protein drugs due to the promising results of a highly specific mechanism of action and reduced toxicity. Despite their prominent roles in disease treatment, delivery of the protein therapeutics is challenging due to chemical instability, immunogenicity and biological barriers. Peptide hydrogels with spatiotemporally tunable properties have shown an outstanding potential to deliver complex protein therapeutics, maintain drug efficacy and stability over time, mimicking the extracellular matrix, and responding to external stimuli. In this review, we present recent advances in peptide hydrogel design strategies, protein release kinetics and mechanisms for protein drug delivery in cellular engineering, tissue engineering, immunotherapy and disease treatments.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Drug Delivery engineering'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles